Noninvasive, site-specific drug delivery technology to deliver compounds to the posterior segments of the eye
There’s no risk. Start your trial today to see profiles of Iomed (Acquired) plus 5051 other startups.
The Medtech Pro Platform has Expanded! Request Demo
Replay LSI2021 Emerging Medtech Summit Play Now
New 2021 Forecasts Released New Data
New 2021 Forecasts Released Learn More
Become a Medtech Market ProLearn More